Objective. To evaluate the frequency, nature, and structure of therapy for uveitis associated with juvenile idiopathic arthritis (JIA) using the data from the Moscow city register of children with rheumatic diseases. Patients and methods. We analyzed the data of 117 patients with JIA and uveitis aged between 3 and 17 years residing in Moscow. Results. JIA-associated uveitis was diagnosed in 11% of children with JIA. It was more common in females than in males (13.1% vs 7.3% respectively). More than half of patients with uveitis (53.8%) had oligoarticular JIA, whereas 34.2% of patients had polyarticular RF-seronegative JIA. The majority of children (85.5%) received basic therapy, primarily with methotrexate (97% of them). Biologicals were administered to 64.1% of patients; of them, 68% received adalimumab. Sixty-one percent of children had bilateral eye lesions. In 41.5% of patients, the disease started with joint syndrome, while 46.3% of patients had both joint syndrome and eye lesions at onset and 12.2% of children initially had eye lesions. Remission of uveitis was registered in 75.6% of patients. Conclusion. Our results are consistent with both Russian and foreign data. Early diagnosis of uveitis and its timely treatment will decrease the incidence of complications in patients with JIA (including complete vision loss) and reduce the burden of disability for patients, their families, and the state. Key words: biological therapy, rheumatoid uveitis, rheumatic diseases in children, juvenile arthritis
SAT0123 RISK FOR TUBERCULOSIS DURING TREATMENT WITH BIOLOGICAL THERAPY: IS IT TIME FOR REVIEWING SCREENING PROTOCOL? – RESULTS FROM BRAZILIAN REGISTRY OF BIOLOGICAL THERAPIES IN RHEUMATIC DISEASES (BIOBADABRASIL)
